Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 2/20 | 0.45 |
| ▸ | MC4R | P32245 | 3/20 | 0.44 |
| ▸ | GLP1R | P43220 | 4/20 | 0.43 |
| ▸ | SCTR | P47872 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 5/20 | 0.43 |
| ▸ | NPY1R | P25929 | 4/20 | 0.43 |
| ▸ | NPY2R | P49146 | 4/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31440231 | 0.90 | KISS1R (0.52) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29958548 | 0.90 | NPY4R (0.49) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30663358 | 0.89 | FOLH1 (0.46) | MC4RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29476475 | 0.89 | FOLH1 (0.45) | MC4RGLP1RSCTRNPY4RNPY1R | |
| SCHEMBL30152128 | 0.89 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29420164 | 0.89 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29697043 | 0.88 | NPY4R (0.53) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29697085 | 0.88 | NPY4R (0.53) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29519652 | 0.88 | NPY4R (0.54) | KISS1RGLP1RSCTRNPY4RNPY1R | |
| SCHEMBL29519546 | 0.88 | NPY4R (0.45) | MC4RGLP1RSCTRNPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861268-B | Cell penetrating peptides and methods of making and using the same | 恩特拉达治疗学股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | KISS1R 2778/4885MC4R 3237/4885GLP1R 751/4885 |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | KISS1R 2778/4885MC4R 3237/4885GLP1R 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.